Barclays lowered the firm’s price target on Aspen Aerogels (ASPN) to $25 from $27 and keeps an Overweight rating on the shares. The company reported “another impressive quarter” and a 50% raise to its 2024 EBITDA guide provide further evidence this is one of the best new energy stories, “and it’s just getting started,” the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASPN:
- Aspen Aerogels price target lowered to $31 from $36 at Roth MKM
- Aspen Aerogels price target lowered to $30 from $41 at TD Cowen
- Aspen Aerogels price target lowered to $28 from $33 at Canaccord
- Aspen Aerogels Reports Strong Q3 Growth and Outlook
- Aspen Aerogels price target lowered to $30 from $38 at Craig-Hallum